BioCentury
ARTICLE | Deals

With CVR, Pacira’s deal for Flexion could nearly double in size

Analgesics company Pacira adds marketed osteoarthritis therapy, with more upside for Flexion shareholders

October 11, 2021 8:38 PM UTC

Pacira’s takeout of Flexion gives the pain management company an osteoarthritis asset that extends its commercial reach while building in further upside for Flexion’s shareholders via a CVR.

Monday’s deal gives Pacira BioSciences Inc. (NASDAQ:PCRX) possession of Zilretta sustained-release triamcinolone acetonide, which Flexion Therapeutics Inc. (NASDAQ:FLXN) has marketed since October 2017. The product, approved to treat osteoarthritis pain of the knee, generated $85.6 million in 2020 revenues, and $52.8 million over the first six months of 2021...